Sanghoon Park

CEO
Illimis Therapeutics, Inc.

​​​​
​​
Dr. Sanghoon Park, Ph.D., MBA, is the Co-founder and Chief Executive Officer of Illimis Therapeutics, a preclinical-stage biopharmaceutical company pioneering the development of glial cell–modulating therapies for neurodegenerative and immune-mediated diseases. With over two decades of experience at the intersection of science, business, and translational medicine, Dr. Park is widely recognized for his leadership in advancing therapeutic strategies that address neuroinflammation and glial dysfunction.
Dr. Park is the inventor of the GAIA (GAS6-mediated Anti-Inflammatory Adaptor) platform, which offers a novel mechanism to mitigate amyloid-related imaging abnormalities (ARIA) and promote neural homeostasis in Alzheimer’s disease. Under his leadership, Illimis has established strategic collaborations with global partners, including Eli Lilly, through the Catalyze360 initiative.
Prior to founding Illimis, Dr. Park held executive and strategic roles at several organizations, including CEO of Amyloid Solution, Chief Strategy Officer at SL-Bigen, and Partner at Partners Investment, a leading Korean healthcare-focused venture capital firm. He earned his Ph.D. in Life Sciences from Pohang University of Science and Technology (POSTECH) and an MBA from Seoul National University.
Dr. Park is committed to fostering cross-disciplinary collaboration and translational innovation in the Asia-Pacific biotech ecosystem. He is a frequent speaker at international conferences and actively contributes to shaping the next generation of neuroimmune therapies.

Clearance of Brain Pathologies via Astrocytes